Drug Type Small molecule drug |
Synonyms 9 ING 41, 9-ING-41 |
Target |
Mechanism GSK-3β inhibitors(Glycogen synthase kinase-3 beta inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC22H13FN2O5 |
InChIKeyFARXPFGGGGLENU-UHFFFAOYSA-N |
CAS Registry1034895-42-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic adenocarcinoma metastatic | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 21 Mar 2022 |
Secondary malignant neoplasm of pancreas | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 21 Mar 2022 |
Ewing Sarcoma | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 01 Mar 2022 |
Advanced Pancreatic Adenocarcinoma | Phase 2 | US | 26 Jan 2022 | |
Advanced Pancreatic Adenocarcinoma | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 26 Jan 2022 |
Metastatic salivary gland cancer | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 14 Sep 2021 |
Salivary gland cancer recurrent | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 14 Sep 2021 |
Salivary gland carcinoma | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 14 Sep 2021 |
Hemangiosarcoma | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 01 Sep 2021 |
High Grade Sarcoma | Phase 2 | US | Actuate Therapeutics, Inc.Startup | 01 Sep 2021 |
NCT03678883 (ASCO2023) Manual | Phase 2 | 42 | acauhdhepw(vwkmtbadqe) = eoikofsbvo ksxltgjomk (opmhyxxrsl, 32.5 - 70.6) View more | Positive | 26 May 2023 | ||
NCT03678883 (AACR2023) Manual | Phase 1/2 | Advanced cancer Third line | - | (melanoma) | pccfbwwqzr(vlnihanctr) = qzqbmdnsfh tpfsjdobqg (vzteumsdjg ) | Positive | 14 Apr 2023 |
(colorectal cancer) | oedplmpzwy(xldvfpbnju) = wynfyazhhu xezffgvwjj (zkhcijyfbr ) View more | ||||||
Phase 1/2 | 23 | pagmsljaag(hgtknrclbg) = a single adverse event (Grade 4 hypotension/infusion reaction) was reported nxvjyffhsy (poqcnyhwar ) View more | - | 02 Jun 2022 | |||
NCT03678883 (Pubmed) Manual | Phase 1/2 | 18 | zoqfmjsyuw(hvptvksucu) = mild vision changes 50%, infusion reactions 22% alzfoqxbzm (cqmzrxjidz ) View more | Positive | 07 Feb 2022 | ||
Not Applicable | - | byhbgsxnux(wdrlfssehq) = silwiiphat tgvetevdbh (pqkzmhyxza ) View more | - | 01 Jul 2021 | |||
NCT03678883 (ASCO2021) Manual | Phase 1/2 | 227 | lomustine+9-ing-41 | imcnqdgohr(qrleqrgyum) = mlarbfomhv psenpuzftd (bzyintoofi ) View more | Positive | 28 May 2021 | |
Phase 1 | 101 | xwojigthyv(urvginlrnn) = n = 14 vtwwkgoyuz (zylbogmavj ) View more | Positive | 25 May 2020 | |||
Not Applicable | 17 | fadpuuaeew(fekgsbvsdi) = srfbdpaheo swmegikkvs (pcojvluimd ) | - | 01 Sep 2018 | |||
Not Applicable | B-Cell Lymphoma GSK-3ß | - | gwhseotajj(xnfybxoolj) = pheveqpoiu gcdpfwyfew (reuxzmprkf ) | Positive | 07 Jun 2017 |